Michael Ryskin
Stock Analyst at B of A Securities
(0)
# 4038
Out of 5,291 analysts
43
Total ratings
45.45%
Success rate
-6.75%
Average return
Main Sectors:
| Name | Action | Price Target | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
Maravai LifeSciences | Maintains: Buy | 9 8 | 2.29 | 249.34% | 3 | Mar 3, 2025 | |
Tempus AI | Maintains: Neutral | 54 60 | 46.98 | 27.71% | 4 | Mar 3, 2025 | |
IDEXX Laboratories | Maintains: Neutral | 475 535 | 415.51 | 28.76% | 2 | Feb 4, 2025 | |
Align Tech | Maintains: Underperform | 200 206 | 157.97 | 30.4% | 6 | Dec 13, 2024 | |
Guardant Health | Maintains: Strong Buy | 28 40 | 42.61 | -6.13% | 1 | Jul 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 10 10 | 5.89 | 61.29% | 1 | Jun 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 11 9 | n/a | n/a | 2 | Jan 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 27 24 | 9.78 | 145.4% | 2 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 27 24 | 16.06 | 49.44% | 2 | Jul 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Buy | 25 | n/a | n/a | 2 | Jun 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 225 180 | 162.32 | 10.89% | 7 | Nov 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Underperform | 90 | n/a | n/a | 3 | Aug 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | n/a | n/a | n/a | 2 | Apr 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 80 52 | 19.63 | 164.9% | 2 | Nov 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Underperform | 17 10 | 2.54 | 293.7% | 2 | Nov 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Underperform | 10 7 | n/a | n/a | 2 | May 14, 2020 |